The procedure of autologous peripheral blood stem cell transplantation (autoPBSCT) requires cryopreservation of cells in a mixture containing dimethyl sulfoxide (DMSO). DMSO is necessary to secure cell viability, however, its infusion may be toxic to stem cell recipient. The aim of this study was to prospectively evaluate the impact of DMSO concentration on engraftment after autoPBSCT.
Introduction
Autologous peripheral blood stem cell transplantation (autoPBSCT) allows for administration of myeloablative conditioning and is widely used for the treatment for hematological malignancies. The procedure requires cryopreservation of hematopoietic stem cells (HSCs) obtained by apheresis and their storage in liquid nitrogen. Addition of cryoprotectant is essential to prevent ice formation during freezing, because ice crystals damage the cells. Dimethyl sulfoxide (DMSO) is the most popular cryoprotectant [1] . To store HSCs, cellular material obtained by apheresis is mixed with cooled cryoprotective mixture: DMSO diluted by human albumin, plasma or another solution licensed for clinical application. In a next step, the suspension of HSCs is divided into aliquots, and slowly cooled to −80°C. The thus prepared cells may be stored in liquid nitrogen for many years. In order to perform transplantation, the suspension is thawed and infused into patient's bloodstream.
Unfortunately, DMSO is harmful for the recipient of HSCs suspension. Adverse events during or after infusion of HSCs are reported in many patients-the most common are malaise, nausea, vomiting, tremors, fever, tachycardia. These reactions may be caused by many factors, e.g. damaged cells that do not survive cryopreservation or too low temperature of infusion, however, it is believed that DMSO is the most toxic component of the transplant material [2] [3] [4] .
Although cryopreservation of HSCs is carried out in many transplant centers and specialized cell banks, there are very few publications about the standardization of cryopreservation procedure. In particular, no prospective studies referring to DMSO concentration were published so far. Due to the lack of evidence-based guidelines, the clinical practice varies among transplant centers. According to surveys performed by the European Society for Blood and Marrow Transplantation, majority of centers use 10% DMSO, while others successfully use lower concentrations [5, 6] .
DMSO may be removed from the graft after thawing by centrifugation the cells or using special devices [4] . It has been shown that DMSO depletion reduced the frequency of adverse effects [7, 8] . Unfortunately, this procedure may be associated with prolonged platelets engraftment [8] . Furthermore, the washing is time consuming and may cause cell clumping or contamination of the product. For this reason, most of transplant centers avoid carrying out this procedure [9] . Another strategy to minimize the final volume and absolute amount of DMSO, is concentrating the cells before cryopreservation [10] . However, once again, there may be a risk of cell clumping after thawing [9] .
The practical and less time-consuming strategy to decrease the amount of DMSO infused to patients is using lower concentration of this cryoprotectant. 5% DMSO in cryoprotective mixture is successfully used by many centers. In a retrospective analysis, Akkök et al. showed that the time of engraftment did not differ between patients, whose cells were cryopreserved in 5 and 10% DMSO [11] . Our group retrospectively compared 7.5% DMSO and 10% DMSO. The time to leukocyte and neutrophil recovery was shorter for patients in the 7.5% DMSO group, however reconstitution of platelets did not differ in both groups [12] .
Optimization of cryopreservation procedure of HSCs requires prospective, comparative studies. The main aim of our one was to evaluate the clinical impact of different DMSO concentrations in cryopreservation mixture (5, 7.5, 10%) on reconstitution of hematopoiesis after autoPBSCT. According to our best knowledge, this is the first randomized study addressing this issue.
Patients and methods

Study design
This was a single-center, prospective, randomized study including adult patients with hematological malignancies or solid tumors, referred for autoPBSCT. Patients were assigned to one of three study groups with different concentrations of DMSO used for cryopreservation: 5, 7.5, and 10%. Our project was approved by the local Bioethics Committee. The study was registered in ClinicalTrials.gov (identifier: NCT02452099) and conducted in accordance with The Declaration of Helsinki. Written informed consent was obtained from all patients.
HSCs mobilization, collection and cryopreservation
Mobilization of stem cells included administration of intermediate-dose cytarabine followed by granulocytecolony stimulating factor (G-CSF) as previously described [13] or the use of G-CSF alone.
To determine the number of CD34+ cells in blood and apheresis product before cryopreservation, flow cytometry analysis was performed according to the ISHAGE guidelines [14] . Cells were diluted and incubated for 20 min., at room temperature, with anti-CD34 antibodies conjugated with phycoerythrin (PE) and anti-CD45 antibodies conjugated with fluorescein isothiocyanate (FITC) (BD Biosciences, San Jose, CA, USA). To remove erythrocytes, the cells were incubated with BD Pharm Lyse™ lysing buffer (BD Biosciences, San Jose, CA, USA). After washing in Cell Wash Buffer (BD Biosciences, San Jose, CA, USA), the cells were suspended in Cell Wash Buffer and analyzed using fluorocytometer FACS Canto (BD Biosciences, San Jose, CA, USA).
The collection was begun when an absolute count of CD34 + cells in blood was higher than 10/µl. The apheresis was performed using Spectra-Optia Apheresis System (CaridianBCT Inc, Lakewood, CO, USA) according to the manufacturer's protocols. Obtained HSCs were cryopreserved immediately after collection or on the next day. In this case, the cell suspension was stored in 4°C, with shaking. During preparation, HSCs were slowly mixed with cold DMSO diluted by autologous plasma. The final cell concentration in freezing bags did not exceed 200 × 10 9 /L. Next, the suspension was divided into 100 ml freezing bags, cryopreserved in controlled-rate IceCube 14 M freezer (SyLab, Neupurkersdorf, Austria) and stored in liquid nitrogen vapor. Controlled-rate programs were separately optimized for 10% DMSO, 7.5% DMSO and 5% DMSO.
Conditioning regimen and transplantation
The conditioning regimen (chemo-or radiotherapy-based) was selected individually following local standard operating procedures. According to the institutional guidelines, patients were reinfused all collected CD34
+ cells if a single transplantation procedure was planned, or half of the material in case of planned double transplantation. To minimize the time of DMSO exposure in the post-thaw period, hematopoietic cell products were thawed close to the bedside using Barkey Plasmatherm (BarkeyGmbH & Co, Germany), and infused directly into the transplant recipient via a central line. Cell viability was determined by trypan blue staining of the pilot vial sample defrosted at the time of administration.
Monitoring of engraftment and adverse effects
The primary end-point of the study was the time to leukocyte, neutrophil and platelet recovery. The incidence of adverse events occurring within 24 h from the beginning of HSCs infusion was secondary end-point. Peripheral blood morphology was examined every day after autoPBSCT, until engraftment. The time to leukocyte and neutrophil recovery was defined as the first of 3 consecutive days, on which absolute cell count in peripheral blood was higher than 1 × 10 9 /L and 0.5 × 10 9 /L, respectively. The time to platelet recovery was defined as the first of 3 consecutive days, on which platelet count in peripheral blood was higher than 20 × 10 9 /L, without platelet transfusion for seven preceding days.
All patients were administered G-CSF starting from day +4 after transplantation to support neutrophil recovery. Platelet transfusions were indicated when the platelet level dropped below 20 × 10 9 /L while packed red blood cell (RBC) transfusions were administered to maintain hemoglobin level >8 g/dL.
Toxicity was assessed using Common Terminology Criteria for Adverse Events Version 4.0.
Statistical methods
Due to lack of reference data from the literature, the assumptions with regard to the study population were arbitrary. The total number of patients planned for randomization was 150. Both, screening and randomization were performed within 5 days prior to start of mobilization regimen. Patients were assigned to one of three study arms in equal proportions. The type of conditioning (irradiation-based vs. chemotherapy-based) was used for stratification. In some cases, however, decision on the choice of conditioning was changed after individual patient randomization.
The differences between three study groups with regard to numerical variables were evaluated using Kruskal-Wallis test while chi [2] test was used in case of categorical variables. Time to hematopoietic recovery and time of hospital stay after PBSCT were estimated using the Kaplan-Meier method. Observations were censored in case of death preceding hematopoietic recovery. The groups were compared with the use of log-rank test. If any difference was detected with p value <0.05, post-hoc analysis was performed comparing three pairs of study groups, separately.
Statistical analysis was performed using Statistica software version 10 (StatSoft Inc., Tulsa, OK, USA).
Results
Patients
One-hundred-fifty patients were randomly assigned to one of three study arms (50 patients each). HSCs obtained by leukapheresis were cryopreserved in three concentrations of DMSO: 5, 7.5, 10%, respectively. One-hundred-forty-three patients proceeded to high dose therapy with autoPBSCT. In 7 cases, the procedure was canceled due to progression or other medical reasons. Results presented in this paper refer to patients actually treated with autoPBSCT.
Patient characteristics are summarized in Table 1 . There were no significant differences regarding age nor the diagnosis.
Characteristic of transplant material
Total volume of cell suspension, transfused into patients was similar (median 400 mL) in all arms (p = 0.95). However, volume of infused DMSO was the lowest in patients who obtained HSCs cryopreserved in 5% DMSO (median 20 mL). The difference was statistically significant in comparison with the groups 7.5 and 10% DMSO (medians 30 mL and 40 mL, p < 0.01).
The viability of nucleated cells on the day of transplantation was similar in all arms (median 96.0% for 10% DMSO group; 96.5% for 7.5% DMSO; 97.0%, for 5% DMSO; p = 0.32).
The dose of transplanted CD34 + cells was comparable in all group: (median 4.78 × 10 6 /kg of recipient body weight for 10% DMSO, 4.22 × 10 6 /kg for 7.5% DMSO and 3.90 × 10 6 for 5% DMSO, p = 0.95) ( Table 2) . 
Adverse effects
The adverse events observed during transplantation or within 24 h after procedure were usually mild to moderate. In 2 cases (one in 5% DMSO group and one in 10% DMSO group), infusions must have been interrupted and continued on the next day due to decrease of capillary blood oxygen saturation.
The most common adverse effects were nausea, vomiting, hypo-or hypertension. Other side reactions varied and included headache, abdominal cramps and others. Total number of patients, who displayed any side effect was 45 (31.5%). The rates were 41.7% for 10% DMSO, 33.3% for 7.5% DMSO and 19.1% for 5% DMSO (Table 2 ). In the post-hoc analysis, the most significant difference was observed between 10 and 5% DMSO (p = 0.02), while the differences between 10% DMSO vs. 7.5% DMSO and 7.5% DMSO vs. 5% DMSO were not statistically significant (p = 0.40 and p = 0.12, respectively).
Hematopoietic recovery
Four patients died shortly after transplantation because of infections (2 from 5% DMSO, 1 from 7.5% DMSO and 1 from 10% DMSO group). In all other patients, successful reconstitution of all hematopoietic lines was observed.
The median time to leukocyte recovery was 10 days in all groups (ranges: 9-12 for 10% DMSO; 7-11 for 7.5% DMSO; and 9-12 for 5% DMSO; p = 0.35). Similar results were obtained for neutrophil engraftment-the median day was 10 in all arms (ranges: 9-12; 8-11 and 9-12, respectively; p = 0.19). The day of platelet recovery >20 × 10 9 /L was similar in all groups: medians were 15 days for 10, 7.5 and 5% DMSO (ranges: 8-20; 0-19; 0-24, respectively; p = 0.79). Hospital stay following transplantation was comparable across all study groups (p = 0.94). The number of days with neutropenic fever did not differ between the arms, as well (p = 0.36) ( Table 2 ).
The number of RBC and platelets transfusion was the same in all arms (medians: 0 and 1, respectively), however, in case of RBC transfusion there were statistical differences between the groups. The average number of transfusion was greatest in the 10% DMSO (Table 2 ). In the post-hoc analysis, the requirement for RBC transfusions was higher for 10% DMSO compared to 7.5% (p = 0.002) and 10% DMSO vs. 5% DMSO (p = 0.02) while there was no statistical difference for the comparison of 7.5% DMSO vs. 5% DMSO (p = 0.6).
Discussion
Despite worldwide use of autoPBSCT, which is associated with the need for stem cell mobilization and storage, the procedure of cryopreservation has not been well standardized so far. In particular, the concentration of DMSO in cryoprotective mixture remains a matter of controversy in view of lack of comparative studies addressing this issue. Our study was the first one that approached the problem prospectively.
As infusion of DMSO may be associated with significant toxicity, it is clinically justified to attempt to reduce its total volume in the transplant material [6] . The easiest way to do it is to reduce its concentration in the cryoprotective mixture. However, too low concentrations may negatively affect its protective function to cells during cryopreservation. Therefore the attempts to reduce DMSO concentration should be stepwise and their safety should be verified in pre-clinical and clinical setting. In our center we performed in vitro studies, as well as pilot clinical experience suggesting that it is possible to decrease DMSO concentration form 10 to 7.5% and further to 5% without affecting the quality of graft [12, 15] .
There are several methods used to assess the quality of transplanted HSCs. The most popular way is to test viability of cells after thawing by their staining using either trypan blue, 7-aminoactinomycin or propidium iodide [16] . In our laboratory, staining using trypan blue is a standard. In the current study we used this method to compare the cells cryopreserved in various concentration of DMSO. No significant differences could be demonstrated.
Determining the viability is very useful, however, it reflects the status of all nucleated cells, while HSCs constitute usually below 5% of the graft. Hence, reliability of this assay is limited. Functional tests of post thaw HSCs, namely clonogeneic assays are believed to be more reliable. These tests demonstrate the ability of cells to proliferate, which may reflect the hematopoietic reconstitutive capacity of HSCs. Unfortunately, these procedures are expensive and time-consuming, and therefore only some centers use them as a part of the quality control [17] .
Assessment of clonogeneic potential of cells cryopreserved in various DMSO concentrations was a subject of our previous study. In short, we prospectively collected the samples of leukapheresis product from patients, divided into portion and frozen with different cryoprotective mixture, containing 10, 7.5, 5 and 2.5% DMSO. The quality of cryoprotective mixture was evaluated based on cells recovery and clonogenic potential of hematopoietic stem cells after thawing. The studies showed comparable results for mixtures contained 10 and 5% DMSO [15] . The same observation was reported by Bakken and coworkers [18] . These data encouraged us to introduce the new composition of the cryoprotective mixture into clinical practice.
In the current study we have chosen the kinetics of hematopoietic recovery after transplantation as the primary end-point. Although from the clinical point of view this is the most relevant parameter, it may be affected by several medical conditions. In particular, protocols of HSCs mobilization, types of conditioning regimen, patient and disease-related factors as well as post-transplant use of colony stimulating growth factors may all affect hematopoietic recovery. Some of these variables are dependent on local standard operating procedures. Therefore, study aiming to assess engraftment in relation to DMSO concentration performed in a single center, as it was in our case, appears more reliable. Patients characteristics were comparable across study groups while all laboratory and clinical procedures were uniform.
The median time to leukocyte, neutrophil, and platelet recovery was exactly the same for all three study groups, indicating that DMSO concentration may be safely reduced from 10 to 7.5% and, further, to 5%. However, more endpoints should be considered to evaluate the quality of autografting [19] . In addition, we analyzed the consumption of platelet and RBC transfusions, number of days with the neutropenic fever and hospital stay since transplantation. No differences between groups could be detected with respect to platelet transfusions, neutropenic fever and number of days in hospital, however consumption of RBC was increased for 10% DMSO concentration with no difference for 7.5% compared to 5%. This observation further supports safety of the lowest DMSO concentration.
Several possible complications related to intravenous injection of DMSO have been described in the literature, including cardiac alterations, nausea, vomiting, allergic reactions, hypotension, hypertension, tremors, and fever [2, 4, 6, 20] . The frequency of adverse reactions may depend on many factors like pre-infusion medication, speed of infusion and total volume of infused DMSO. Furthermore, it's very difficult to isolate the effect of infusion from the effect of conditioning therapy.
The frequency of adverse events during transplantation and within the next 24 h was secondary study end-point. The most common side reaction that we have observed were nausea, vomiting, weakness and hypo-or hypotension. As could have been expected, the total volume of infused DMSO was strictly related to its concentration in cryoprotective mixture, being twice lower for 5% compared to 10% DMSO. We observed a statistically significant difference in the frequency of side effects between the groups. The highest proportion of patients experiencing side effects was observed in 10% DMSO, the lowest in 5% DMSO arms. This observation is in line with the data of other authors who have shown that toxicity of HSCs infusion is correlated with total dose of DMSO [6] [7] [8] . All these authors point out that proper preparation of transplant material is crucial for safety of patients during infusion. This issue may be especially important for patients requiring more than one leukapheresis, when the total volume of cell suspension is relatively high.
Decrease in transplantation toxicity may be achieved by several strategies, including washing the cells before infusion or splitting the transplantation procedure in separate infusions performed on consecutive days [6] . According to results of our study, reduction of DMSO concentration in cryoprotective mixture, which is an easy and less timeconsuming approach, is effective in minimizing overall amount of infused DMSO and therefore the incidence of adverse events.
In summary, results of our study indicate that the reduction in the DMSO concentration from 10% to 7.5 and 5% does not influence hematopoietic recovery after autoPBSCT and may result in improved tolerance of stem cell infusion. In view of our findings, 5% DMSO in cryopreservation mixture should be considered a new standard for cryopreservation of HSCs.
